Related references
Note: Only part of the references are listed.Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma
Yifei Chen et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2021)
Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma A meta-analysis of randomized controlled trials
Peng Zhu et al.
MEDICINE (2021)
Tumor-infiltrating lymphocyte quantification stratifies early-stage human papillomavirus oropharynx cancer prognosis
Farhoud Faraji et al.
LARYNGOSCOPE (2020)
Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy
Mark Lee et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma A Study of 1034 Patients
Talia L. Fuchs et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy
Martina Strudel et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Andrea Botticelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer
Bruna Cerbelli et al.
VIRCHOWS ARCHIV (2020)
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
Jiahang Mo et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis
Ashley Lau et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
Alessio Cortellini et al.
EUROPEAN JOURNAL OF CANCER (2020)
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
Andrea Botticelli et al.
VACCINES (2020)
The 5-Ws of immunotherapy in head and neck cancer
Andrea Botticelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Paolo Marchetti et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
The prognostic and predictive value of tumor infiltrating Macrophage and Neutrophil in patient with clear cell renal cell carcinoma: Tumor infiltrating lymphocytes in renal cell carcinoma
Weiqiang Xu et al.
MEDICINE (2020)
Cetuximab Plus Chemotherapy versus Chemotherapy Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
Yitian Lang et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Sex Hormones and Anticancer Immunity
Berna C. Ozdemir et al.
CLINICAL CANCER RESEARCH (2019)
Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
Elie El Rassy et al.
FUTURE ONCOLOGY (2019)
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
Andrea Botticelli et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
Benedetto Sacchetti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Joel Guigay et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Advances in the Management of HPV-Related Oropharyngeal Cancer
F. De Felice et al.
JOURNAL OF ONCOLOGY (2019)
The immune response-related mutational signatures and driver genes in non-small-cell lung cancer
Hao Chen et al.
CANCER SCIENCE (2019)
Macrophages and Metabolism in the Tumor Microenvironment
Ilio Vitale et al.
CELL METABOLISM (2019)
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
Mehmet Asim Bilen et al.
BMC CANCER (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Kyung Hwan Kim et al.
CLINICAL CANCER RESEARCH (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Andrew W. Hahn et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
P. S. Chowdhury et al.
JOURNAL OF INTERNAL MEDICINE (2018)
First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Christopher J. D. Wallis et al.
EUROPEAN UROLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions
Rothschild Uta et al.
SWISS MEDICAL WEEKLY (2018)
The Confluence of Sex Hormones and Aging on Immunity
Melanie R. Gubbels Bupp et al.
FRONTIERS IN IMMUNOLOGY (2018)
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
S. N. Gettinger et al.
NATURE COMMUNICATIONS (2018)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis
Kentaro Inamura et al.
LUNG CANCER (2017)
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Andrea Botticelli et al.
ONCOTARGET (2017)
Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma
Yubo Jiang et al.
ONCOTARGET (2017)
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Bruna Cerbelli et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Human papillomavirus-related oropharyngeal cancer
M. Taberna et al.
ANNALS OF ONCOLOGY (2017)
The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review
Sheila V. Graham
CLINICAL SCIENCE (2017)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutational signatures associated with tobacco smoking in human cancer
Ludmil B. Alexandrov et al.
SCIENCE (2016)
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
J. Guigay et al.
ANNALS OF ONCOLOGY (2015)
Ranking treatments in frequentist network meta-analysis works without resampling methods
Gerta Ruecker et al.
BMC MEDICAL RESEARCH METHODOLOGY (2015)
Immunology and Immunotherapy of Head and Neck Cancer
Robert L. Ferris
JOURNAL OF CLINICAL ONCOLOGY (2015)
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Assuntina G. Sacco et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
Joseph M. Curry et al.
SEMINARS IN ONCOLOGY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
HPV and head and neck cancer
X. Dufour et al.
EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES (2012)
Network meta-analysis, electrical networks and graph theory
Gerta Ruecker
RESEARCH SYNTHESIS METHODS (2012)
T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer
A. E. Albers et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Head and neck cancer: Changing epidemiology, diagnosis, and treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2008)
Recent advances in head and neck cancer
Robert I. Haddad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
